GlassScriptPhysician profile
Nelson C Echebiri
NPI 1780973305
$549.36
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $34.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $159.70 | 2019 | |
| Allergan, INC. | $54.49 | 2019 | |
| Duchesnay USA Incorporated | $52.24 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.14 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $45.97 | 2019-2020 | |
| Hologic Sales and Service, LLC | $44.81 | 2019 | |
| Lupin INC. | $29.72 | 2019 | |
| Exeltis, USA INC. | $21.95 | 2019 | |
| Astellas Pharma US INC | $21.20 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.69 | 2019 | |
| Therapeuticsmd, INC. | $14.80 | 2019 | |
| Mission Pharmacal Company | $13.72 | 2019 | |
| Millicent US INC | $12.02 | 2019 | |
| Avion Pharmaceuticals | $10.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Echebiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.